Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) for its Rosuvastatin calcium tablets indicated for lowering cholesterol levels.
According to a release, the Hyderabad-based Aurobindo is eligible for 180 days of generic drug shared exclusivity and the product has been launched in the US market. Rosuvastatin calcium tablets are the generic version of Crestor tablets of IPR Pharmaceuticals, Inc.
Rosuvastatin calcium tablets had annual sales of around $6.78 billion in the 12 months ending May 2016, according to IMS.
Aurobindo’s scrip gained 3.78 per cent on the Bombay Stock Exchange on Wednesday and was trading at Rs 787.75 at noon.